Kidney biopsy has long been a test that medicine approaches with caution, especially when the patient is older, has weakened kidneys, or takes drugs that thin the blood. A prospective study of 1,096 such high-risk procedures, to be presented at ASN Kidney Week 2026, suggests that a carefully ordered pathway can turn that caution into confidence. Led by Dario Roccatello of the University of Turin, the work reports that structured preparation, guided technique, and careful follow-up kept serious harm rare, and that many of the feared warning signs did not predict it. Whether this quiet disciplin
Standardized ROCKY Protocol Makes High-Risk Kidney Biopsies Safer, Study Finds
No kidney removals, no procedure-related deaths among 1,096 high-risk biopsies
Mark
Why does a 0.8% severe complication rate matter so much here?
Mimi
Because these were not easy cases. Every one of the 1,096 biopsies involved a patient with predefined high-risk features, and still there were no kidney removals and no procedure-related deaths.
Mark
And the usual warning signs didn't predict trouble?
Mimi
Older age, impaired kidney function, and blood-thinning drugs were not independently linked to severe complications. That's the part that could change how doctors weigh a decision.
Luke
Careful with "changes." This is one program's protocol, and the source doesn't say how many centers were involved. We know the numbers, not whether they hold elsewhere.
Mark
What is the protocol, concretely?
Mimi
Structured assessment beforehand, correction of risk factors, ultrasound-guided biopsy, and systematic monitoring afterward.
Luke
Worth noting that there's no comparison group described. We can't say how these patients would have fared without ROCKY. The finding is that complications were rare under it, not that it beat something else.
Mark
What about outpatient biopsies?
Mimi
Severe complication rates weren't significantly different from inpatient ones. Roccatello says that supports expanding outpatient programs.
Luke
That expansion is his interpretation, and it's a potential benefit. Any savings in hospital stays or resources weren't measured in what we've been given. Also, this is a presentation at a meeting, so the full details aren't yet laid out for us to check.
Der Puls
- A test that matters for diagnosis is often withheld from the very patients who may need it most, because of age, weak kidneys, or blood-thinning medication.
- Serious complications struck only 0.8% of 1,096 high-risk biopsies, and no kidney was lost and no patient died.
- Researchers are testing whether a structured ROCKY checklist, from pre-procedure assessment to ultrasound guidance and close monitoring, can make the difference.
- Familiar red flags did not independently predict severe harm, and outpatient biopsies performed as safely as inpatient ones.
- The findings are headed to ASN Kidney Week, where outside centres will judge whether the results hold up beyond their origin.
Kidney biopsy has long been a test that medicine approaches with caution, especially when the patient is older, has weakened kidneys, or takes drugs that thin the blood. A prospective study of 1,096 such high-risk procedures, to be presented at ASN Kidney Week 2026, suggests that a carefully ordered pathway can turn that caution into confidence. Led by Dario Roccatello of the University of Turin, the work reports that structured preparation, guided technique, and careful follow-up kept serious harm rare, and that many of the feared warning signs did not predict it. Whether this quiet discipline can travel beyond the centre where it was built remains the open question.
Kidney biopsy is one of the foundational tests in kidney medicine, yet for certain patients the health system tends to hesitate before ordering it. A prospective study to be presented at ASN Kidney Week 2026 suggests that hesitation may be larger than the danger justifies, as long as the procedure follows a standardized pathway.
The study tested a protocol called ROCKY, which uses structured checkpoints to extract the most diagnostic value from each biopsy while keeping bleeding and other complications as low as possible. Across 1,096 biopsies performed in patients with predefined high-risk features, severe complications occurred in just 0.8%. No patient lost a kidney, no one died from the procedure, and diagnostic accuracy was achieved every time.
Two findings challenge common assumptions. Older age, impaired kidney function, and antiplatelet or anticoagulant treatment were not independently linked to severe complications, and outpatient procedures were as safe as inpatient ones.
Dario Roccatello of the University of Turin, the corresponding author, argues that biopsy can be done safely even in patients traditionally considered at increased risk, provided the pathway includes careful pre-procedure assessment, correction of risk factors, ultrasound guidance, and systematic monitoring afterward. For patients who might otherwise be turned away because of age, kidney disease, obesity, dialysis, or anatomical differences, this could mean access to an important diagnostic test. Because outpatient care proved comparable, he also sees a case for expanding outpatient biopsy programs, which could reduce unnecessary hospital stays.
The work will face scrutiny at Kidney Week. The next test is whether other centres adopt the ROCKY checkpoints and achieve similar results outside the setting where the protocol was born.
A kidney biopsy is one of the foundational tests in kidney medicine, and for certain patients it is also one the medical system tends to hesitate over. A prospective study to be presented at ASN Kidney Week 2026, October 22 to 25, suggests that hesitation may be larger than the risk warrants, provided the procedure follows a standardized pathway.
The study tested a protocol called ROCKY, short for Renal-biopsy Optimized Care and Knowledge Yielding safety. It uses structured checkpoints designed to do two things at once: get the most diagnostic value out of each biopsy and keep complications, bleeding in particular, as low as possible. The published title describes it as a prospective validation of the protocol for high-risk kidney biopsy across 1,000 procedures over 10 years.
The actual count was 1,096 biopsies, all performed in patients with predefined high-risk features. Severe complications occurred in 0.8% of them. No patient lost a kidney, and no one died from the procedure. Diagnostic accuracy was achieved in every procedure.
Two further findings cut against common assumptions. First, the factors usually treated as red flags, including older age, impaired kidney function, and treatment with antiplatelet or anticoagulant drugs, were not independently associated with severe complications. Second, severe complication rates did not differ significantly between inpatient and outpatient procedures.
The corresponding author is Dario Roccatello, MD, PhD, of the University of Turin in Italy. He says kidney biopsy can be done safely even in patients traditionally considered at increased risk, when it takes place within a rigorous, standardized pathway. That pathway includes a structured assessment before the biopsy, correction of risk factors, ultrasound guidance during the procedure, and systematic monitoring afterward.
Roccatello points to what is at stake for patients. In his view, the findings may widen access for people who might otherwise be refused an important diagnostic and prognostic procedure because of age, kidney impairment, obesity, antithrombotic treatment, dialysis, or anatomical abnormalities.
He also draws a conclusion about where the procedure is done. Because outpatient safety was comparable, he argues the results support expanding outpatient biopsy programs, which could reduce unnecessary hospital stays and make better use of healthcare resources.
The work will be presented at Kidney Week, where it will be open to scrutiny. What to watch is whether other centers adopt the ROCKY checkpoints and see similar results outside the setting where the protocol was developed.
Bemerkenswerte Zitate
Kidney biopsy can be performed safely even in patients traditionally considered at increased procedural risk when undertaken within a rigorous, standardized pathway.— Dario Roccatello, MD, PhD, University of Turin
Möchten Sie die ganze Geschichte?
Das Original lesen bei News-Medical ↗
Science & Space